635.54
-1.16 (-0.18%)
| Penutupan Terdahulu | 636.70 |
| Buka | 627.91 |
| Jumlah Dagangan | 501,083 |
| Purata Dagangan (3B) | 508,701 |
| Modal Pasaran | 50,748,710,912 |
| Harga / Pendapatan (P/E TTM) | 48.70 |
| Harga / Pendapatan (P/E Ke hadapan) | 42.73 |
| Harga / Jualan (P/S) | 11.49 |
| Harga / Buku (P/B) | 30.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Keuntungan | 22.76% |
| Margin Operasi (TTM) | 31.70% |
| EPS Cair (TTM) | 10.82 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 3.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 73.16% |
| Nisbah Semasa (MRQ) | 1.16 |
| Aliran Tunai Operasi (OCF TTM) | 968.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 761.15 M |
| Pulangan Atas Aset (ROA TTM) | 22.98% |
| Pulangan Atas Ekuiti (ROE TTM) | 59.33% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | IDEXX Laboratories, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.63 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.67% |
| % Dimiliki oleh Institusi | 97.51% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Elyxium Wealth, Llc | 31 Dec 2025 | 5,419,507 |
| Polen Capital Management Llc | 31 Dec 2025 | 960,537 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 800.00 (Barclays, 25.88%) | Beli |
| 800.00 (BTIG, 25.88%) | Beli | |
| Median | 775.00 (21.94%) | |
| Rendah | 730.00 (UBS, 14.86%) | Pegang |
| Purata | 770.00 (21.16%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 637.13 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 09 Feb 2026 | 750.00 (18.01%) | Pegang | 639.79 |
| Barclays | 05 Feb 2026 | 800.00 (25.88%) | Beli | 643.59 |
| BTIG | 03 Feb 2026 | 800.00 (25.88%) | Beli | 632.56 |
| UBS | 03 Feb 2026 | 730.00 (14.86%) | Pegang | 632.56 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results |
| 15 Jan 2026 | Pengumuman | Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus |
| 15 Jan 2026 | Pengumuman | IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs |
| 13 Jan 2026 | Pengumuman | IDEXX Announces CEO Succession |
| 09 Jan 2026 | Pengumuman | IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |